Drug Trial Radar · NCT06141486
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
943
Actual
Start
Dec 27, 2023
Primary completion
Mar 24, 2028
Study completion Mar 24, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This event-driven study will end when the target number of 6-month cCDP events is achieved, and the study is expected to last 43 months from randomization of the first participant to the common study end. * The number of scheduled visits will be up to 25 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months. * If the prespecified number of events for 6-month cCDP is not reached by V21/W180, scheduled visits will continue every 3 months.
Conditions
- Multiple Sclerosis
Interventions
FrexalimabDrug
SAR441344 Solution for IV infusion
PlaceboDrug
Solution for IV infusion
MRI contrast-enhancing agentsDrug
IV, as per respective label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months in the double-blind treatment periodTime frame: Up to 36 months
Locations
311 sites in 27 countries. Site status is shown where the registry gives one.
Alabama Neurology Associates- Site Number : 8400115
Homewood, Alabama
Perseverance Research Center- Site Number : 8400138
Scottsdale, Arizona
Imaging Endpoints- Site Number : 8400050
Scottsdale, Arizona
Sutter East Bay Medical Foundation - Berkeley- Site Number : 8400134
Berkeley, California
University of California Irvine - School of Medicine- Site Number : 8400143
Irvine, California
University of California San Diego - La Jolla- Site Number : 8400095
La Jolla, California
Kaiser Permanente - Los Angeles Medical Center- Site Number : 8400184
Los Angeles, California
Hoag Memorial Hospital Presbyterian- Site Number : 8400031
Newport Beach, California
Stanford Neuroscience Health Center- Site Number : 8400120
Palo Alto, California
Private Practice - Dr. Regina Berkovich- Site Number : 8400005
West Hollywood, California
University of Colorado - Anschutz Medical Campus- Site Number : 8400001
Aurora, Colorado
Advanced Neurology of Colorado- Site Number : 8400148
Fort Collins, Colorado
Yale University School of Medicine- Site Number : 8400081
New Haven, Connecticut
Hartford Healthcare Medical Group- Site Number : 8400069
Norwich, Connecticut
MedStar Georgetown University Hospital- Site Number : 8400044
Washington D.C., District of Columbia
Neurology of Central Florida- Site Number : 8400147
Altamonte Springs, Florida
MS & Neuromuscular Center of Excellence- Site Number : 8400015
Clearwater, Florida
Norman Fixel Institute for Neurological Diseases (FIND)- Site Number : 8400054
Gainesville, Florida
Neurology Associates - Maitland- Site Number : 8400010
Maitland, Florida
Orlando Health Neuroscience Institute - Downtown Pavilion- Site Number : 8400060
Orlando, Florida
Axiom Clinical Research of Florida- Site Number : 8400049
Tampa, Florida
University of South Florida- Site Number : 8400013
Tampa, Florida
Palm Beach Neurology- Site Number : 8400105
West Palm Beach, Florida
Joi Life Wellness Group LLC- Site Number : 8400192
Smyrna, Georgia
Rush University Medical Center- Site Number : 8400102
Chicago, Illinois
University of Chicago Medical Center- Site Number : 8400055
Chicago, Illinois
Consultants in Neurology- Site Number : 8400020
Northbrook, Illinois
Neuroscience Institute Center- Site Number : 8400053
Merrillville, Indiana
University of Iowa- Site Number : 8400029
Iowa City, Iowa
University of Kansas Medical Center- Site Number : 8400084
Kansas City, Kansas
Baptist Health Lexington- Site Number : 8400149
Lexington, Kentucky
NeuroMedical Clinic of Central Louisiana- Site Number : 8400159
Alexandria, Louisiana
Ochsner Medical Center - Jefferson Highway- Site Number : 8400027
New Orleans, Louisiana
University of Maryland School of Medicine - Baltimore- Site Number : 8400185
Baltimore, Maryland
Johns Hopkins Hospital- Site Number : 8400080
Baltimore, Maryland
Tufts Medical Center- Site Number : 8400003
Boston, Massachusetts
Boston Clinical Trials- Site Number : 8400178
Boston, Massachusetts
Neurology Center of New England- Site Number : 8400164
Foxborough, Massachusetts
The Elliot Lewis Center- Site Number : 8400033
Wellesley, Massachusetts
UMass Memorial Medical Center - University Campus- Site Number : 8400028
Worcester, Massachusetts
Showing 40 of 311 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.